Featured Research

from universities, journals, and other organizations

Photodynamic Therapy Shows Promise In Halting Progression Of Age-Related Macular Degeneration

Date:
April 19, 2000
Source:
Emory University Health Sciences Center
Summary:
Photodynamic therapy (PDT), a treatment for age-related macular degeneration under study at Emory University and other sites, has received Food and Drug Administration (FDA) approval. Emory Eye Center can now offer new hope to patients with the wet form of age-related macular degeneration (AMD), the leading cause of blindness in Americans over age 50.

April 13, 2000 -- Photodynamic therapy (PDT), a treatment for age-related macular degeneration under study at Emory University and other sites, received Food and Drug Administration (FDA) approval today.

Emory Eye Center can now offer new hope to patients with the wet form of age-related macular degeneration (AMD), the leading cause of blindness in Americans over age 50.

PDT is significant because there is no cure for wet AMD and the most widely available treatment -- photocoagulation therapy with a heating laser -- can cause blind spots and can be used for about 10 percent of patients with the disease. About 40 to 60% of the estimated 200,000 patients who are diagnosed each year with wet AMD may be eligible for PDT.

According to Paul Sternberg Jr., M.D., director of the retina section at the Emory Eye Center, "PDT uses a combination of low-level laser light with a drug to stop the macula-destroying effects of the disorder. PDT is a promising alternative to the growing number of treatments we now can offer macular degeneration patients. The therapy appears to be is safer with fewer risks than photocoagulation therapy."

AMD affects more than one-fourth of all Americans over age 75. No one knows what causes the disorder or how to prevent it. AMD affects central part of the retina or the macula, the area of sharpest sight and the part we use for reading and central vision.

The wet or exudative form of AMD -- the most blinding form -- results when abnormal blood vessels form and leak fluid and blood underneath the retina in the layer of the retina in the back of the eye called the choroid. The choroid's blood vessels, combined with tissue, can form a scar-like membrane under the retina and block central vision.

The goal of PDT is to seal leaking blood vessels and slow or stop the progression of vision loss. During PDT, the patient receives an injection of a photosensitizer drug that concentrates in the abnormal blood vessels from the choroid. A non-thermal laser light shone onto the retina activates the drug. The therapy is outpatient and patients can return to normal activities immediately, though they will need to stay out of direct sunlight for at least 24 hours. Most need repeat treatments later to enhance results.

Following treatments, patients sometimes will experience a temporary reduction of vision, which will improve over the next few weeks. Research shows that the therapy preserves or improves vision (defined as no loss of visual acuity or a deterioration of less than four acuity lines on an eye chart) in 38% of patients and slows vision loss in another 31 percent.

The Emory Eye Center was one of about 30 centers worldwide that participated in Phase III clinical trials carried out by CIBA Vision of Atlanta (QLT PhotoTherapeutics of Vancouver, Canada, makes the dye and Carl Zeiss makes the laser). The therapy is marketed as Visudyne™ therapy.


Story Source:

The above story is based on materials provided by Emory University Health Sciences Center. Note: Materials may be edited for content and length.


Cite This Page:

Emory University Health Sciences Center. "Photodynamic Therapy Shows Promise In Halting Progression Of Age-Related Macular Degeneration." ScienceDaily. ScienceDaily, 19 April 2000. <www.sciencedaily.com/releases/2000/04/000417100606.htm>.
Emory University Health Sciences Center. (2000, April 19). Photodynamic Therapy Shows Promise In Halting Progression Of Age-Related Macular Degeneration. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/04/000417100606.htm
Emory University Health Sciences Center. "Photodynamic Therapy Shows Promise In Halting Progression Of Age-Related Macular Degeneration." ScienceDaily. www.sciencedaily.com/releases/2000/04/000417100606.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins